Mehmet Oz, head of the US Centers for Medicare & Medicaid Services (CMS), said the Trump administration is seeking additional voluntary drug-pricing agreements with pharmaceutical companies. Officials have announced more than 20 such deals so far, Oz said, and more are in the works. The agreements vary, but companies typically agree to lower prices charged to public health programs and to launch new drugs at prices comparable with other developed countries in exchange for tariff relief.